First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation Meeting Abstract
| Authors: | Guo, R.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S.; Calvo, E.; Sonpavde, G. P.; Awad, M.; Riess, J. W.; Hernandez Guerrero, T. C.; Herzberg, B.; Italiano, A.; Swalduz, A.; Lorusso, P.; Smit, E. F.; Garon, E. B.; Novotny, W.; Yap, T. A. |
| Abstract Title: | First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sept 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S483 |
| End Page: | S484 |
| Language: | English |
| ACCESSION: | WOS:001326612900597 |
| DOI: | 10.1016/j.annonc.2024.08.670 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 603O -- Source: Wos |
